Wee1

Wee1製品

All (7)
Wee1阻害剤 (6)
新製品

製品コード	製品名称	製品説明	文献中Selleckの製品使用例	お客様のフィードバック
S1525	Adavosertib (MK-1775)	アダボセルチブ (Adavosertib (MK-1775、AZD1775)) は、無細胞アッセイで IC50 が 5.2 nM の強力かつ選択的な Wee1 阻害剤です。G2 DNA 損傷チェックポイントを阻害します。臨床フェーズ2。	Cancer Cell, 2025, 43(8):1530-1548.e9 Nat Cancer, 2025, 10.1038/s43018-025-00960-z Cell Rep Med, 2025, S2666-3791(25)00102-8
S8148	PD0166285	PD0166285 is a potent Wee1 and Chk1 inhibitor with activity at nanomolar concentrations (IC50=24 nM for Wee1 and 72 nM for Myt1). PD0166285 is also a novel G2 checkpoint abrogator. PD0166285 induces apoptosis.	iScience, 2025, 28(5):112292 Signal Transduct Target Ther, 2024, 9(1):181. Nat Commun, 2024, 15(1):2089
F0602	Phospho-Wee1 (Ser642) Antibody [P3A10]
S9778	Debio 0123	WEE1-IN-5 (Debio 0123) is a potent Wee1 inhibitor that inhibits phospho-CDC2 and abrogates the G2 check point.	J Clin Invest, 2025, 135(11)e188165 medRxiv, 2024, 2023.05.17.23290140
E1000	Azenosertib (Zn-C3)	Azenosertib (Zn-C3) is an oral active, highly effective and selective Wee1 inhibitor with IC50 of 3.9 nM, which can be used in cancer research.	bioRxiv, 2025, 2025.05.28.656693 medRxiv, 2024, 2023.05.17.23290140
E1175	lunresertib (RP-6306)	lunresertib (RP-6306) is a Protein Kinase, Membrane Associated Tyrosine/Threonine 1 (PKMYT1) inhibitor, which can be used for the research of cancer.	Cell Rep, 2025, 44(8):116019 BMC Cancer, 2024, 24(1):1333
E4737	Potrasertib	Potrasertib (IMP7068, WEE1-IN-10) is a potent and selective inhibitor of WEE1 Kinase. It displays antitumor activity and is well-tolerated in patients with advanced solid tumors.
S1525	Adavosertib (MK-1775)	アダボセルチブ (Adavosertib (MK-1775、AZD1775)) は、無細胞アッセイで IC50 が 5.2 nM の強力かつ選択的な Wee1 阻害剤です。G2 DNA 損傷チェックポイントを阻害します。臨床フェーズ2。	Cancer Cell, 2025, 43(8):1530-1548.e9 Nat Cancer, 2025, 10.1038/s43018-025-00960-z Cell Rep Med, 2025, S2666-3791(25)00102-8
S8148	PD0166285	PD0166285 is a potent Wee1 and Chk1 inhibitor with activity at nanomolar concentrations (IC50=24 nM for Wee1 and 72 nM for Myt1). PD0166285 is also a novel G2 checkpoint abrogator. PD0166285 induces apoptosis.	iScience, 2025, 28(5):112292 Signal Transduct Target Ther, 2024, 9(1):181. Nat Commun, 2024, 15(1):2089
S9778	Debio 0123	WEE1-IN-5 (Debio 0123) is a potent Wee1 inhibitor that inhibits phospho-CDC2 and abrogates the G2 check point.	J Clin Invest, 2025, 135(11)e188165 medRxiv, 2024, 2023.05.17.23290140
E1000	Azenosertib (Zn-C3)	Azenosertib (Zn-C3) is an oral active, highly effective and selective Wee1 inhibitor with IC50 of 3.9 nM, which can be used in cancer research.	bioRxiv, 2025, 2025.05.28.656693 medRxiv, 2024, 2023.05.17.23290140
E1175	lunresertib (RP-6306)	lunresertib (RP-6306) is a Protein Kinase, Membrane Associated Tyrosine/Threonine 1 (PKMYT1) inhibitor, which can be used for the research of cancer.	Cell Rep, 2025, 44(8):116019 BMC Cancer, 2024, 24(1):1333
E4737	Potrasertib	Potrasertib (IMP7068, WEE1-IN-10) is a potent and selective inhibitor of WEE1 Kinase. It displays antitumor activity and is well-tolerated in patients with advanced solid tumors.

Wee1シグナル伝達経路